Mateon Therapeutics, Inc.
(Other OTC/NBB : OXGN)

( )
OXGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.82%132.300.0%$1592.67m
OCGNOcugen, Inc. -14.25%8.970.0%$993.97m
NVAXNovavax, Inc. -13.89%158.1092.9%$973.00m
AMGNAmgen, Inc. -0.91%221.911.3%$586.84m
REGNRegeneron Pharmaceuticals, Inc. 0.59%449.382.7%$521.53m
VRTXVertex Pharmaceuticals, Inc. -0.31%207.791.9%$503.86m
GILDGilead Sciences, Inc. 0.77%63.231.0%$499.99m
ILMNIllumina, Inc. -4.03%399.613.5%$482.11m
BIIBBiogen, Inc. -1.14%263.571.7%$367.21m
ALXNAlexion Pharmaceuticals, Inc. 0.18%148.462.0%$360.83m
CRSPCRISPR Therapeutics AG -3.02%115.490.6%$268.32m
BNGOBioNano Genomics, Inc. -19.30%6.900.0%$265.49m
EXASEXACT Sciences Corp. -4.39%121.0218.4%$224.11m
SGENSeagen Inc. -1.68%145.455.8%$204.38m
VXRTVaxart, Inc. -6.92%5.920.0%$174.35m

Company Profile

Mateon Therapeutics, Inc. is a biopharmaceutical company. It engages in developing anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The firm operates through the following segments: PointR, Mateon/Oxigene and Oncotelic. The PointR segment develops vision grid/cluster computing/AI to support drug development. The Mateon/Oxigene segment develops Vascular Disrupting Agent (CA4P and Oxi4503). The Oncotelic segment develops OT-101, an antisense against TGF-beta- for the treatment of cancers. Mateon Therapeutics was founded in 1988 and is headquartered in Agoura Hills, CA.